Claims for Patent: 8,784,808

Summary for Patent: 8,784,808

Title:	Fc.gamma.RIIB specific antibodies and methods of use thereof
Abstract:	The present invention relates to antibodies or fragments thereof that bind Fc.gamma.RIIB with greater affinity than said antibodies or fragments binds Fc.gamma.RIIA. The invention encompasses the use of such antibodies or fragments for the treatment of diseases related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune diseases, inflammatory diseases or IgE-mediated allergic disorders. The present invention also encompasses the use of such antibodies and fragments in combination with other cancer therapies, methods of enhancing the therapeutic effect of therapeutic antibodies, and methods of enhancing efficacy of vaccine compositions.
Inventor(s):	Johnson; Leslie S. (Darnestown, MD), Huang; Ling (Bethesda, MD)
Assignee:	MacroGenics, Inc. (Rockville, MD)
Application Number:	13/367,626
Patent Claims:	1. A method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of: I. a humanized antibody or an antigen-binding fragment thereof that specifically binds to the extracellular domain of native human Fc.gamma.RIIB with a greater affinity than said antibody binds to the extracellular domain of native human Fc.gamma.RIIA, wherein said humanized antibody or antigen-binding fragment thereof comprises a human framework region and: (A) (1) a polypeptide comprising the amino acid sequence of SEQ ID NO. 1 (CDR1 of the heavy chain of humanized antibody 2B6), SEQ ID NO. 2 (CDR2 of the heavy chain of humanized antibody 2B6), and SEQ ID NO. 3 (CDR3 of the heavy chain of humanized antibody 2B6), and (2) a polypeptide comprising the amino acid sequence of SEQ ID NO. 8 (CDR1 of the light chain of humanized antibody 2B6), SEQ ID NO. 11 (CDR2 of the light chain of humanized antibody 2B6), and SEQ ID NO. 12 (CDR3 of the light chain of humanized antibody 2B6); or (B) (1) a polypeptide comprising the amino acid sequence of SEQ ID NO. 29 (CDR1 of the heavy chain of humanized antibody 3H7), SEQ ID NO. 30 (CDR2 of the heavy chain of humanized antibody 3H7), and SEQ ID NO. 31 (CDR3 of the heavy chain of humanized antibody 3H7), and (2) a polypeptide comprising the amino acid sequence of SEQ ID NO. 38 (CDR1 of the light chain of humanized antibody 3H7), SEQ ID NO. 39 (CDR2 of the light chain of humanized antibody 3H7), and SEQ ID NO. 40 (CDR3 of the light chain of humanized antibody 3H7); and in combination with II. an antibody that specifically binds said cancer antigen and is cytotoxic. 2. The method of claim 1, wherein said humanized antibody or antigen-binding fragment thereof comprises said polypeptide (A)(1) and (A)(2). 3. The method of claim 1, wherein said humanized antibody or antigen-binding fragment thereof comprises said polypeptide (B)(1) and (B)(2). 4. The method of claim 1, wherein said antigen-binding fragment comprises an F(ab').sub.2 fragment or a F(ab) fragment of said humanized antibody. 5. The method of claim 1, wherein said polypeptide (A)(1) and (A)(2) are covalently bonded to one another, or said polypeptide (B)(1) and (B)(2) are covalently bonded to one another. 6. The method of claim 1, wherein said cancer is breast, ovarian, prostate, cervical, B-cell, or pancreatic cancer. 7. The method of claim 1, wherein said cytotoxic antibody is trastuzumab, rituximab, an anti-CD14 antibody, edrecolomab, cetuximab, a humanized anti-.alpha.V.beta.3 integrin antibody, a humanized anti-CD52 IgG1, epratuzumab, or a murine anti-CD20 antibody. 8. The method of claim 1, wherein said cancer antigen is MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, p15, beta-catenin, MUM-1, CD20, CDK4, HER-2/neu, human papillomavirus-E6, human papillomavirus-E7, or MUC-1. 9. The method of claim 1, wherein said cancer antigen is a breast, ovarian, prostate, cervical, B-cell or pancreatic carcinoma antigen. 10. The method of claim 1, further comprising the administration of one or more additional cancer therapies. 11. The method of claim 10, wherein said additional cancer therapy is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, or surgery. 12. The method of claim 1, wherein said patient is human. 13. A method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of a humanized antibody or an antigen-binding fragment thereof that specifically binds to the extracellular domain of native human Fc.gamma.RIIB with a greater affinity than said antibody binds to the extracellular domain of native human Fc.gamma.RIIA, wherein said humanized antibody or said antigen-binding fragment thereof possesses CDR1, CDR2 and CDR3 from an antibody heavy chain, and CDR1, CDR2 and CDR3 from an antibody light chain, and wherein said humanized antibody or fragment thereof comprises: (1) a polypeptide comprising the amino acid sequence of SEQ ID NO. 1 (CDR1 of the heavy chain of humanized antibody 2B6), SEQ ID NO. 2 (CDR2 of the heavy chain of humanized antibody 2B6), and SEQ ID NO. 3 (CDR3 of the heavy chain of humanized antibody 2B6); or (2) a polypeptide comprising the amino acid sequence of SEQ ID NO. 8 (CDR1 of the light chain of humanized antibody 2B6), SEQ ID NO. 11 (CDR2 of the light chain of humanized antibody 2B6), and SEQ ID NO. 12 (CDR3 of the light chain of humanized antibody 2B6); or (3) a polypeptide comprising the amino acid sequence of SEQ ID NO. 29 (CDR1 of the heavy chain of humanized antibody 3H7), SEQ ID NO. 30 (CDR2 of the heavy chain of humanized antibody 3H7), and SEQ ID NO. 31 (CDR3 of the heavy chain of humanized antibody 3H7); or (4) a polypeptide comprising the amino acid sequence of SEQ ID NO. 38 (CDR1 of the light chain of humanized antibody 3H7), SEQ ID NO. 39 (CDR2 of the light chain of humanized antibody 3H7), and SEQ ID NO. 40 (CDR3 of the light chain of humanized antibody 3H7); and wherein the administered antibody reduces the population of cancer cells expressing Fc.gamma.RIIB. 14. The method of claim 13, wherein said humanized antibody or antigen-binding fragment thereof comprises said polypeptides (1) and (2). 15. The method of claim 13, wherein said humanized antibody or antigen-binding fragment thereof comprises said polypeptides (3) and (4). 16. The method of claim 13, wherein said antigen-binding fragment comprises an F(ab').sub.2 fragment or a F(ab) fragment of said humanized antibody. 17. The method of claim 14, wherein said polypeptides (1) and (2) are covalently bonded to one another. 18. The method of claim 15, wherein said polypeptides (3) and (4) are covalently bonded to one another. 19. The method of claim 13, wherein said cancer is breast, ovarian, prostate, cervical, B-cell, or pancreatic cancer. 20. The method of claim 13, comprising the further step of administering in combination with said humanized antibody or antigen-binding fragment thereof a cytotoxic antibody that specifically binds said cancer antigen, wherein said cytotoxic antibody is trastuzumab, rituximab, an anti-CD14 antibody, edrecolomab, cetuximab, a humanized anti-.alpha.V.beta.3 integrin antibody, a humanized anti-CD52 IgG1, epratuzumab, or a murine anti-CD20 antibody. 21. The method of claim 13, wherein said cancer antigen is a breast, ovarian, prostate, cervical, B-cell or pancreatic carcinoma antigen. 22. The method of claim 13, further comprising the administration of one or more additional cancer therapies. 23. The method of claim 22, wherein said additional cancer therapy is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, or surgery. 24. The method of claim 13, wherein said humanized antibody or antigen-binding fragment thereof has the binding characteristics of an antibody produced from a hybridoma cell line having ATCC accession number PTA-4591. 25. The method of claim 13, wherein said humanized antibody or antigen-binding fragment thereof has the binding characteristics of an antibody produced from a hybridoma cell line having ATCC accession number PTA-4592.

Details for Patent 8,784,808

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2024-05-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2024-05-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-05-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-05-10
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2024-05-10
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2024-05-10
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2024-05-10